Abstract
In the 15 years that have elapsed since the publication of Fauci et al.’s seminal view on vasculitis1, there has been significant growth in our understanding of this enigmatic group of disorders. Advances in basic and clinical research have resulted in new concepts concerning the aetiology, immunology, and pathophysiology of the vasculitides, and new proposals for the diagnosis and classification of these diseases. More importantly, new and innovative therapies have been proposed based on current formulations of the immunopathogenesis of the blood vessel damage. Most of this information is immediately relevant for the practising clinician, who is faced with the formidable task of diagnosing and treating these difficult patients. This review will summarize our current understanding of vasculitis affecting the peripheral nervous system and outline the diagnosis and clinical management of these patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis. Clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med. 1978;89:660–76.
Cupps TR, Fauci AS. The vasculitides. In: Smith LM, ed. Major problems in internal medicine. Vol. 21. Philadelphia: WB Saunders, 1981:6–19.
Hunder GG, Arend WP, Block DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum. 1990;33:1065–7.
Bloch DA, Michel BA, Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum. 1990;33:1068–73.
Moore PM, Cupps TR. Neurologic complications of vasculitis. Ann Neurol. 1983;14: 155–67.
Cohen SB, Hurd ER. Neurological complications of connective tissue and other ‘collagen-vascular’ diseases. Semin Arthritis Rheum. 1981;11:190–212.
Moore PM, Fauci AS. Neurologic manifestations of systemic vasculitis. A retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients. Am J Med. 1981;71:517–24.
Sigal LH. The neurologic presentation of vasculitis and rheumatologic syndromes. Medicine. 1987;66:157–80.
Kissel JT, Slivka AP, Warmolts JR, et al. The clinical spectrum of necrotizing angiopathy of the peripheral nervous system. Ann Neurol. 1985;18:251–7.
Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain. 1987;110:843–54.
Hawke SHB, Davies L, Pamphlett R, Guo Y-P, Pollard JD, McLeod JG. Vasculitic neuropathy. A clinical and pathological study. Brain. 1991;114:2175–90.
Smiley JD, Moore M. Immune complex vasculitis: role of complement and IgG-Fc receptor functions. Am J Med Sci. 1989;298:267–77.
McDougal JS, McDuffie FC. Immune complexes in man: detection and clinical significance. Adv Clin Chem. 1985;24:1–60.
Cornacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest. 1983;71:236–47.
Becherer JD, Alsenz J, Servic C, et al. Cell surface proteins reacting with activated complement components. Complement Inflamm. 1989;6:142–65.
Fauci AS. The vasculitic syndromes. In: Wilson JD, Braunwald E, Issellbacher KJ, et al. (eds). Harrison’s Principles of Internal Medicine. New York: McGraw Hill, 1991;1456–63.
Savage COS, Ng YC. The aetiology and pathogenesis of major systemic vasculitides. Postgrad Med J. 1986;62:627–36.
Hogg N. The structure and function of Fe receptors. Immunol Today. 1988;9:185–7.
Moore PM. Immune mechanisms in the primary and secondary vasculitides. J Neurol Sci. 1989;93:129–45.
Kissel JT, Riethman JL, Omerza J, et al. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol. 1989;25:291–7.
Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;4:875–80.
Ryan US. The endothelial surface and responses to injury. Fed Proc. 1986;45:101–8.
Pangyres PK, Blumbergs PC, Leong AS-Y, Bourne AJ. Vasculitis of peripheral nerve and skeletal muscle: clinicopathological correlation and immunopathic mechanisms. J Neurol Sci. 1990;100:193–202.
Pober JS, Cotran R. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427–51.
Cavender DE. Organ-specific and non-organ-specific lymphocyte receptors for vascular endothelium. J Invest Dermatol. 1990;94(suppl.):41–85.
Brasile L, Kremer JM, Clarke JL. Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis. Am J Med. 1989;87:74–80.
Frampton G, Jayne DRW, Perry GJ et al. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol. 1990;82:227–32.
Editorial. Antibodies to endothelial cells. Lancet. 1991;337:649–50.
Gaskin G, Savage COS. Immune markers in vasculitis. Br J Hosp Med. 1991;46:104–6.
Ferraro G, Meroni PL, Tincani A et al. Anti-endothelial cell antibodies in patients with Wegener’s granulomatosis and micropolyarteritis. Clin Exp Immunol. 1990;79:47–53.
Goeken JA. Antineutrophil cytoplasmic antibody - a useful serological marker for vasculitis. 7 Clin Immunol. 1991;11:161–74.
Parlevliet KJ, Henzen-Logmans SC, Oe PL, et al. Antibodies to components of neutrophil cytoplasm: a new diagnostic tool in patients with Wegener’s granulomatosis and systemic vasculitis. Q J Med. 1988;66:55–63.
Egner W, Chapel HM. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol. 1990;82: 244–9.
Lai KN, Jayne DRW, Brownlee A, Lockwood CM. The specificity of anti-neutrophil cytoplasm antibodies in systemic vasculitides. Clin Exp Immunol. 1990;82:233–7.
Bleil L, Manger B, Winkler TH, et al. The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. J Rheumatol. 1991;18:1199–206.
Ewert BH, Jennette JC, Falk RJ. The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis. 1991;18:188–95.
Nolte B, Specks U, Liidemann J et al. Anticytoplasmic antibodies: their immunodiagnostic value in Wegener’s granulomatosis. Ann Intern Med. 1989;111:28–40.
Panegyres PK, Faull RJ, Russ GR, Appleton SL, Wangel AG, Blumbergs PC. Endothelial cell activation in vasculitis of peripheral nerve and skeletal muscle. J Neurol Neurosurg Psychiatry. 1992;55:4–7.
Shuki H, Shimokama T, Watanabe T. Temporal arteritis. Cell composition and the possible pathogenetic role of cell-mediated immunity. Hum Pathol. 1989;20:1057–64.
Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener’s granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med. 1983;74:700–4.
Grau GE, Roux-Lombard P, Gysler C et al. Serum cytokine changes in systemic vasculitis. Immunology. 1989;68:196–8.
Grau GE, Piguet PF, Vassalli P, Lambert PH. Involvement of tumour necrosis factor and other cytokines in immune-mediated vascular pathology. Int Arch Allergy Appl Immunol. 1989;88:34–9.
Braquet P, Hosford D, Braquet M, et al. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol. 1989;88:88–100.
Mancardi GL, Cadoni A, Zicca A et al. HLA-DR Schwann cell reactivity in peripheral neuropathies of different origins. Neurology. 1988;38:848–51.
Nukada H, Dyck PJ. Acute ischemia causes axonal stasis, swelling, attenuation and secondary demyelination. Ann Neurol. 1987;22:311–18.
Said G, Laxroix-Ciaudo C, Fujimura H et al. The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol. 1988;23:461–5.
Fujimura H, Lacroix C, Said G. Vulnerability of nerve fibers to ischaemia. A quantitative light and electron microscope study. Brain. 1991;114:1929–42.
Dyck P, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy: three-dimensional morphology of fiber degeneration related to sites of occluded vessels. Mayo Clin Proc. 1972;47:461–75.
Wees SJ, Sunwoo IN, Oh SJ. Sural nerve biopsy in systemic necrotizing vasculitis. Am J Med. 1981;71:525–32.
Harati Y, Niakan E. The clinical spectrum of inflammatory-angiopathic neuropathy. J Neurol Neurosurg Psychiatry. 1986;49:1313–16.
Bouche P, Leger JM, Travers MA et al Peripheral neuropathy in systemic vasculitis: clinical and electrophysiologic study of 22 patients. Neurology. 1986;36:1598–602.
Olney RK. Neuropathies in connective tissue disease. Muscle Nerve. 1992;15:531–42.
Ropert A, Metral S. Conduction block in neuropathies with necrotizing vasculitis. Muscle Nerve. 1990;13:102–5.
Jamieson PW, Guiliani MJ, Martinez AJ. Necrotizing angiopathy presenting with multifocal conduction blocks. Neurology. 1991;41:442–4.
Kissel JT, Mendell JR. Vasculitic neuropathy. Neurol Clin. 1992;10:761–81.
Scott DGI. Classification and treatment of systemic vasculitis. Br J Rheumatol. 1988;27: 251–7.
Haynes BF, Allen NB, Fauci AS. Diagnostic and therapeutic approach to the patient with vasculitis. Med Clin North Am. 1986;70:355–68.
Axelrod L. Glucocorticoids. In: Kelley WN, Harris ED, Ruddy S et al., editors. Textbook of Rheumatology. New York: WB Saunders, 1989;845–61.
Dalakas M. Pharmacologic concerns of corticosteroids in the treatment of patients with immune-related neuromuscular diseases. Neurol Clin. 1990;8:93–118.
Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Eng] J Med. 1992;326: 1473–9.
Stillwell TJ, Benson RC, DeRemee RA et al. Cyclophosphamide-induced bladder toxicity in Wegener’s granulomatosis. Arthritis Rheum. 1988;31:465–70.
Katz P, Fauci AS. Immunosuppressives and immunoadjuvants. In: Samter M, Talmage DW, Frank MM et al., editors, Immunological Disease. Boston: Little Brown, 1988: 675–98.
Kisel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology. 1986;36:35–9.
Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281–5.
Kissel JT, Rammohan KW. Pathogenesis and therapy of nervous system vasculitis. Clin Neuropharmacol. 1991;14:28–48.
Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301:235–8.
Leib ES, Restivo C, Paulus HE Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med. 1979;67:941–7.
Fauci AS, Haynes BF, Katz P et al. Wegener’s granulomatosis: prospective and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76–85.
Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer. 1991;68:1430–6.
Schwartz SA. Intravenous immunoglobulin (IVIG) in the therapy of autoimmune disorders. J Clin Immunol. 1990;10:81–9.
Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107–16.
Jaynes DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991;337:1137–9.
Conn DL. Update on systemic necrotizing vasculitis. Mayo Clin Proc. 1989;64:535–43.
Huse WD, Lakshmi S, Iverson SA et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989;246:1275–81.
Mathieson PW, Cobbold SP, Hale G et al. Monoclonal antibody therapy in systemic vasculitis. N Engl J Med. 1990;323:250–4.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Kissel, J.T., Mendell, J.R. (1994). Peripheral neuropathy due to vasculitis: immunopathogenesis, clinical features and treatment. In: Hohlfeld, R. (eds) Immunology of Neuromuscular Disease. Immunology and Medicine Series, vol 24. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1422-6_4
Download citation
DOI: https://doi.org/10.1007/978-94-011-1422-6_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4622-0
Online ISBN: 978-94-011-1422-6
eBook Packages: Springer Book Archive